- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Legend Biotech Corp (LEGN)
Legend Biotech Corp stock price live, this page displays NASDAQ LEGN stock exchange data. View the LEGN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Legend Biotech Corp real time stock price chart below.
What Is the Legend Biotech Corp Stock Price Today?
The Legend Biotech Corp stock price today is 38.45.
What Is the Stock Symbol for Legend Biotech Corp?
The stock symbol for Legend Biotech Corp is ""LEGN.""
What Stock Exchange Does Legend Biotech Corp Trade On?
Legend Biotech Corp is listed and trades on the NASDAQ stock exchange.
Is Legend Biotech Corp a Good Stock to Buy?
Determining whether Legend Biotech Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LEGN quote. (ISIN: US52490G1022)
What Is the Legend Biotech Corp Stock Price Today?
The Legend Biotech Corp stock price today is 38.45.
What Is the Stock Symbol for Legend Biotech Corp?
The stock symbol for Legend Biotech Corp is ""LEGN.""
What Stock Exchange Does Legend Biotech Corp Trade On?
Legend Biotech Corp is listed and trades on the NASDAQ stock exchange.
Is Legend Biotech Corp a Good Stock to Buy?
Determining whether Legend Biotech Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LEGN quote. (ISIN: US52490G1022)
38.45
-0.35(-0.90%)
Closed·
Pre Market
39.50+1.05(+2.73%)
·
Fair Value
An estimate of a Legend Bio's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
38.24
39.10
52 wk Range
27.34
59.62
LEGN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 6 days
More Info
Fair Value
An estimate of a Legend Bio's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
38.2439.10
52 wk Range
27.3459.62
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LEGN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Legend Bio's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
76.29
Upside
+98.41%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Legend Biotech Corp Company Profile
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey.
Legend Biotech Corp SWOT Analysis
Carvykti's Triumph | Legend Biotech's Carvykti shows strong efficacy in multiple myeloma treatment, with sales nearly doubling year-over-year and projections reaching $1.9 billion by 2025 |
Manufacturing Ambitions | Explore Legend's plans to expand Carvykti production capacity to 10,000 doses by 2025 and 20-24,000 doses by 2027, potentially generating over $10 billion in revenue |
Analyst Optimism | Average price target of $81 from various analysts, with a Strong Buy consensus reflecting confidence in Legend Biotech's growth potential and market positioning |
Pipeline Potential | Delve into Legend's diverse pipeline, including promising therapies for gastric, esophageal, and lung cancers, offering multiple avenues for future growth beyond Carvykti |
Legend Biotech Corp Earnings Call Summary for Q1/2025
- Legend Biotech's Q1 2025 revenue reached $195M, up 137% YoY, driven by CARVICTI sales of $369M (135% YoY growth)
- Net loss of $101M reported, with adjusted net loss at $27M; stock rose 3.46% in pre-market trading to $33.5
- Company aims for CARVICTI operational breakeven by end of 2025 and company-wide profitability in 2026
- Expansion plans include increasing market presence in Europe and US, and developing an in vivo CAR T platform
- Analysts project 63% revenue growth for FY2025; stock considered undervalued with price targets ranging from $53.12 to $95.00
Last Updated: 13/05/2025, 14:26
Read Full TranscriptCompare LEGN to Peers and Sector
Metrics to compare | LEGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLEGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −32.5x | −3.3x | −0.5x | |
PEG Ratio | −0.60 | −0.19 | 0.00 | |
Price/Book | 7.0x | 2.5x | 2.6x | |
Price / LTM Sales | 9.7x | 12.7x | 3.3x | |
Upside (Analyst Target) | 97.7% | 166.1% | 43.5% | |
Fair Value Upside | Unlock | −1.1% | 6.3% | Unlock |
Analyst Ratings
19 Buy
1 Hold
0 Sell
Ratings:
20 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 76.29
(+98.41% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.27 / -0.21
Revenue / Forecast
195.05M / 192.54M
People Also Watch
FAQ
What Stock Exchange Does Legend Bio Trade On?
Legend Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Legend Bio?
The stock symbol for Legend Bio is "LEGN."
What Is the Legend Bio Market Cap?
As of today, Legend Bio market cap is 7.09B.
What Is Legend Bio's Earnings Per Share (TTM)?
The Legend Bio EPS (TTM) is -1.19.
When Is the Next Legend Bio Earnings Date?
Legend Bio will release its next earnings report on 10 Aug 2025.
From a Technical Analysis Perspective, Is LEGN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Legend Bio Stock Split?
Legend Bio has split 0 times.
How Many Employees Does Legend Bio Have?
Legend Bio has 2700 employees.
What is the current trading status of Legend Bio (LEGN)?
As of 05 Aug 2025, Legend Bio (LEGN) is trading at a price of 38.45, with a previous close of 38.45. The stock has fluctuated within a day range of 38.24 to 39.10, while its 52-week range spans from 27.34 to 59.62.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.